PO105 Levodopa-induced dyskinesias in parkinson’s: imaging of striatal dat density over time

    loading  Checking for direct PDF access through Ovid



The density of the dopamine transporter (DAT) continues to decline in the striatum of Parkinson’s disease (PD) patients, while they get at risk for developing levodopa-induced dyskinesias (LIDs). Here, we studied the role of DAT-specific imaging as a prognostic marker of dyskinesias.


We retrospectively selected 42 PD patients who had SPECT imaging with 123I-Ioflupane approximately five years ago during the diagnosis of PD. 15 patients of them were rescanned with 123I-Ioflupane SPECT after 6.3±3.0 years. We divided the PD patients according to the presence or absence of dyskinesias. SPECT data were analysed for the putamen by a semi-quantification approach.


10 PD patients had developed LIDs, while 32 were non-dyskinetic. The putaminal mean 123I-Ioflupane uptake in the LIDs (1.7±0.4) group was not statistically different as compared to the non-LIDs group (1.7±0.5;p>010). All 15 PD patients who had a second SPECT scan showed significant reductions in the putaminal 123I-Iofluplane uptake (p<0.001) as compared to their first scan. Within this subgroup, the LIDs (n=8) had significantly lower DAT uptake (1.1±0.3) as compared to the non-LIDs patients (n=7); (1.5±0.5; p<0.05).


123I-Ioflupane SPECT imaging in de novo PD, cannot predict the onset of LIDs within five years from diagnosis. As shown in the group that repeated 123I-Ioflupane SPECT imaging, the onset of LIDs may be linked to a faster decline of putaminal DAT availability.

Related Topics

    loading  Loading Related Articles